Notably, our model indicates that fibroblast growth factor receptor 4 (FGFR4), a receptor tyrosine kinase, has potential as a therapeutic target in NSCLC, which has been also found in another study [18]. Here, FGFR4 is linked to non-small cell lung carcinoma.